The MET Amplification NSCLC Test is a specialized diagnostic procedure designed to identify the amplification of the MET gene in patients with non-small cell lung cancer (NSCLC). This genetic alteration can influence tumor growth and spread, making it a critical target for personalized cancer therapy. The test is performed on a sample of the tumor tissue to detect the presence and extent of MET gene amplification, which can guide oncologists in tailoring the most effective treatment plans for their patients.
Administered at DNA Labs UAE, a leading facility in genetic and molecular diagnostics, the test employs advanced genomic technologies to ensure precise and reliable results. With a focus on providing comprehensive support for cancer management, DNA Labs UAE offers this test at a cost of 1800 AED. The investment in such a test is crucial for patients with NSCLC, as it opens the door to targeted therapies that can significantly improve treatment outcomes and quality of life.
The MLC1 Gene Mutation Analysis, also known as the Agrawal Mutation Test, is a specialized genetic test conducted to identify mutations in the MLC1 gene, which are associated with various neurological conditions. This test plays a critical role in the diagnosis and management of diseases related to MLC1 gene mutations, enabling healthcare professionals to tailor treatments based on the specific genetic makeup of an individual. The test cost is set at 1800 AED and is available at DNA Labs UAE, a leading facility equipped with state-of-the-art technology for genetic testing and analysis. By providing accurate and reliable results, DNA Labs UAE aids in the early detection and intervention of conditions linked to MLC1 gene mutations, ultimately contributing to better patient outcomes.
The MYD88 Gene Mutation Analysis Test is a specialized diagnostic procedure aimed at identifying mutations within the MYD88 gene, a critical component in the immune response and signaling pathways within cells. This test is particularly relevant for patients suspected of having conditions that are linked to MYD88 mutations, such as certain types of lymphomas and other hematological malignancies. By analyzing the genetic material extracted from a patient's blood or tissue sample, this test can pinpoint specific alterations in the MYD88 gene that may contribute to disease pathogenesis or influence treatment strategies.
Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, the MYD88 Gene Mutation Analysis Test is priced at 1800 AED. This cost reflects the comprehensive nature of the analysis, including the sophisticated technology and expert interpretation involved in identifying and understanding the implications of MYD88 gene mutations. For patients and healthcare providers, the results of this test can be invaluable in guiding clinical decisions, tailoring personalized treatment plans, and ultimately improving patient outcomes.
The N-Myc Oncogene Test is a sophisticated diagnostic procedure aimed at detecting amplifications or abnormalities in the N-Myc gene, which is often associated with various types of cancer, including neuroblastoma, a common cancer in children that affects the nerve tissues. This test plays a crucial role in identifying the presence of N-Myc gene amplifications, which can influence the aggressiveness of the cancer and guide treatment decisions.
Performed at DNA Labs UAE, a state-of-the-art facility known for its advanced genetic testing capabilities, the test involves analyzing a patient's DNA sample to look for specific changes in the N-Myc oncogene. These insights are invaluable for oncologists in determining the prognosis of the disease and tailoring personalized treatment plans that can significantly improve patient outcomes.
The cost of the N-Myc Oncogene Test at DNA Labs UAE is set at 1800 AED. While the price might seem significant, the value it provides in terms of precise diagnosis and guiding effective treatment strategies is invaluable for patients facing cancers associated with N-Myc gene alterations.
The NPM1 Gene Fragment Analysis Test is a specialized diagnostic examination conducted at DNA Labs UAE, designed to detect mutations in the NPM1 gene. These mutations are significant because they are often associated with acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. By analyzing fragments of the NPM1 gene, this test helps in identifying specific genetic alterations that can influence treatment decisions and prognostic assessments for patients diagnosed with AML.
The cost of the NPM1 Gene Fragment Analysis Test at DNA Labs UAE is 1800 AED. This test is a crucial step in the personalized medicine approach, offering insights that can lead to targeted therapies tailored to the genetic profile of the individual's cancer. Conducted in a state-of-the-art facility, the test ensures accuracy and reliability, providing essential information for both patients and healthcare providers in the management of acute myeloid leukemia.
The NTRK1 Test is a specialized diagnostic procedure designed to detect alterations in the NTRK1 gene, which can play a crucial role in the development and progression of various cancers. This gene encodes for a protein that is involved in the growth and division of cells, and mutations in NTRK1 can lead to abnormal cell growth, potentially resulting in cancer. The test is particularly significant for patients with tumors that may be driven by NTRK gene fusions, as it can help in guiding targeted therapy options.
Conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the NTRK1 Test is performed using sophisticated molecular techniques to ensure accuracy and reliability. The cost of the test is 1800 AED, reflecting the comprehensive analysis and detailed insights it provides. By identifying NTRK1 gene alterations, healthcare providers can tailor treatment strategies more effectively, offering hope for better outcomes in patients affected by cancers associated with these genetic changes.
The NTRK2 test is a specialized diagnostic procedure aimed at detecting genetic alterations in the NTRK2 gene, which can play a significant role in the development and progression of various types of cancers. This gene encodes for a protein that is involved in the growth and survival of nerve cells, and mutations within this gene can lead to abnormal cell growth and cancer. The test is particularly relevant for patients who may benefit from targeted therapy, as identifying NTRK2 gene alterations can help in customizing treatment plans to improve outcomes.
Performed at DNA Labs UAE, a leading facility in genetic testing and analysis, the NTRK2 test utilizes advanced molecular techniques to accurately identify mutations within the NTRK2 gene. The test is conducted under stringent laboratory conditions to ensure high levels of accuracy and reliability. With a cost of 1800 AED, the test is an investment in personalized medicine, offering crucial information that can guide treatment decisions and potentially lead to better patient outcomes. DNA Labs UAE is equipped with state-of-the-art technology and staffed by experienced professionals, ensuring that patients receive comprehensive and precise genetic testing services.
The NTRK3 test is a specialized diagnostic tool available at DNA Labs UAE, designed to detect alterations in the NTRK3 gene, which can play a crucial role in the development and progression of certain types of cancer. This gene is involved in the encoding of neurotrophic tyrosine receptor kinase type 3, a protein that can affect cell growth and division. Alterations or mutations in the NTRK3 gene are associated with various cancers, making this test an important part of personalized cancer treatment planning.
By identifying specific genetic mutations, healthcare providers can tailor treatment strategies to target the genetic makeup of the cancer, potentially improving patient outcomes. The NTRK3 test is performed using a sample of the patient's tissue or blood, utilizing advanced genetic sequencing technologies to accurately identify mutations in the NTRK3 gene.
At DNA Labs UAE, the cost of the NTRK3 test is set at 1800 AED. The test is conducted in a state-of-the-art laboratory setting by experienced professionals, ensuring high-quality and reliable results. This test represents a critical step forward in the field of precision medicine, offering hope for more effective and personalized cancer treatment options.
The PIK3CA Mutation Analysis Exon 7, 9, and 20 Test is a specialized diagnostic procedure designed to identify mutations in the PIK3CA gene, particularly focusing on exons 7, 9, and 20. This gene plays a crucial role in cell growth and division, and mutations within it are often associated with various cancers, including breast, colorectal, and endometrial cancers. By pinpointing specific alterations in these exons, healthcare professionals can gain valuable insights into the molecular underpinnings of a patient's cancer, which can, in turn, guide personalized treatment decisions.
The test is conducted at DNA Labs UAE, a reputable facility known for its state-of-the-art genetic testing services. The cost of the test is 1800 AED, which reflects the comprehensive analysis and detailed insights it provides. By utilizing advanced molecular techniques, DNA Labs UAE ensures accurate and reliable results, making the PIK3CA Mutation Analysis Exon 7, 9, and 20 Test a valuable tool in the arsenal against cancer.
The RET NSCLC Test is a specialized diagnostic procedure aimed at detecting rearrangements in the RET gene, which are implicated in the development of non-small cell lung cancer (NSCLC). This test is crucial for patients diagnosed with NSCLC as it helps in identifying whether they are candidates for targeted therapy that specifically addresses RET gene mutations. Conducted at DNA Labs UAE, a leading facility in genetic testing, this test offers precise and reliable results. The cost of the RET NSCLC Test is 1800 AED, reflecting the sophisticated technology and expertise involved in conducting this advanced molecular diagnostic test. By identifying the genetic alterations in the RET gene, healthcare providers can tailor treatment plans to improve outcomes and quality of life for NSCLC patients.
